NIV-002 and Other Targets

Drugs promoting brain neuroplasticity are expected to be beneficial across multiple classes of brain ailments. Combination drugs – combining three FDA-approved drugs – can better address the wide range of damage that results from brain diseases and brain injuries. Our combination drugs are designed to promote cell repair/growth and boost the signaling between brain cells while also combating inflammation and cell damage and death from the inflammation (see discussion here).

Our first drug (NIV-001) has been engineered to promote remodeling, rewiring, and recovery after a patient has suffered a stroke. We expect our second drug (NIV-002) to address the impairments resulting from Traumatic Brain Injury and Concussion.

This condition has much in common with the damage resulting from stroke.

We foresee the need for neuroplastic-enhancing drugs in the fight against dementia and movement disorders, depression, immune system attacks, neuro/psychiatric disorders, and cognition deficits (see the list of potential targets). A healthy brain is critical to surviving but also thriving.

Potential Neuroplasicity Targets

Injury to Central Nervous System

  • Stroke
  • Traumatic Brain Injury & Concussion
  • PTSD, CTE, Spinal Cord Injury
  • Injury by addiction or disease

Dementia & Movement Disorders

  • Alzheimer’s, Parkinson’s, Huntington’s, ALS

Headaches & Depression

  • Chronic Migraine, Depression, Bipolar

Immune System Attack

  • Multiple Sclerosis, Muscular Dystrophy, Rheumatoid Arthritis, Lupus, Myasthenia Gravis, Guillain-Barre


  • Cerebral Palsy, Schizophrenia, Epilepsy, Autism, Dyslexia

Cognition Deficits

  • Long COVID, Cancer Chemo Fog, Anesthetic Fog, Chronic Fatigue, Fibromyalgia